Subjects | Outcome | Number of eventsa | Q2 versus Q1 | Q3 versus Q1 | Q4 versus Q1 | Pfor linear trend |
---|---|---|---|---|---|---|
HR (95% CI) | HR (95% CI) | HR (95% CI) | ||||
All subjects | All-cause mortality | 8.39 | 1.05 (0.77 to 1.43) | 1.29 (0.96 to 1.73) | 1.63 (1.22 –to 2.17) | <0.001*** |
Cancer mortality | 3.88 | 1.07 (0.69 to 1.68) | 1.47 (0.96 to 1.25) | 1.60 (1.04 to 2.43) | 0.014* | |
CVD mortality | 2.34 | 1.24 (0.67 to 2.29) | 1.30 (0.71 to 2.36) | 1.94 (1.09 to 3.42) | 0.016* | |
Mortality from causes other than cancer and CVD | 2.16 | 0.92 (0.50 to 1.68) | 1.08 (0.60 to 1.93) | 1.49 (0.86 to 2.60) | 0.096 | |
Men | All-cause mortality | 11.14 | 0.98 (0.67 to 1.45) | 0.98 (0.68 to 1.42) | 1.50 (1.08 to 2.09) | 0.020* |
Cancer mortality | 4.92 | 1.54 (0.86 to 2.75) | 1.23 (0.68 to 2.21) | 1.96 (1.15 to 3.35) | 0.027* | |
CVD mortality | 3.13 | 0.74 (0.34 to 1.61) | 0.86 (0.43 to 1.72) | 1.41 (0.76 to 2.60) | 0.208 | |
Mortality from causes other than cancer and CVD | 3.09 | 0.65 (0.03 to 1.40) | 0.86 (0.44 to 1.67) | 1.15 (0.62 to 2.12) | 0.557 | |
Women | All-cause mortality | 6.30 | 1.45 (0.86 to 2.46) | 1.57 (0.91 to 2.71) | 2.04 (1.22 to 2.34) | 0.004* |
Cancer mortality | 3.13 | 1.51 (0.77 to 2.99) | 1.25 (0.59 to 2.62) | 1.62 (0.81 to 3.23) | 0.295 | |
CVD mortality | 1.74 | 1.18 (0.36 to 3.86) | 1.91 (0.61 to 6.00) | 2.73 (0.93 to 8.06) | 0.012* | |
Mortality from causes other than cancer and CVD | 1.46 | 1.66 (0.52 to 5.25) | 2.17 (0.68 to 6.96) | 2.40 (0.78 to 7.38) | 0.106 |